Journal
GROWTH FACTORS
Volume 29, Issue 4, Pages 140-152Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/08977194.2011.595411
Keywords
TGF-beta; Smad; ALK5; fibrosis; cancer; clinical trial
Categories
Funding
- Swedisch Cancerfonden
- Netherlands Organization of Scientific Research
- Netherlands Institute for Regenerative Medicine (NIRM)
- Dutch Cancer Society [UL2011-5051]
- Centre for Biomedical Genetics
Ask authors/readers for more resources
On the basis of these observations, small molecule inhibitors of the TGF-beta beta receptor kinases, neutralizing antibodies that interfere with ligand--receptor interactions, antisense oligonucleotides reducing TGF-beta beta expression, and soluble receptor ectodomains that sequester TGF-beta beta have been developed to intervene with excessive TGF-beta beta signaling activity in the aforementioned disorders. Here, we review the current state of anti-TGF-beta beta therapy in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
